<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03634124</url>
  </required_header>
  <id_info>
    <org_study_id>NIMAO/2017-01/ECN-01</org_study_id>
    <nct_id>NCT03634124</nct_id>
  </id_info>
  <brief_title>Generation of Thrombin and Prediction of Deep Vein Thrombosis Post Prosthetic Orthopedic Surgery of the Lower Limbs</brief_title>
  <acronym>GT-PT</acronym>
  <official_title>Generation of Thrombin and Prediction of Deep Vein Thrombosis Post Prosthetic Orthopedic Surgery of the Lower Limbs</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nīmes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nīmes</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The numerical ratio between the value of the thrombin generation test performed without&#xD;
      soluble thrombomodulin and the value of the thrombin generation test performed in the&#xD;
      presence of soluble thrombomodulin, performed pre-surgically, could predict the risk of early&#xD;
      venous thromboembolism after placement of total hip or knee prosthesis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 21, 2019</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Estimate the numerical ratio between the value of the thrombin generation test performed without soluble thrombomodulin and the value of the thrombin generation test performed in the presence of soluble thrombomodulin</measure>
    <time_frame>Day 0</time_frame>
    <description>Numerical value</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of Symptomatic pulmonary embolism</measure>
    <time_frame>Day 7 (± 2)</time_frame>
    <description>yes/non</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of Symptomatic deep vein thrombosis somewhere in the body</measure>
    <time_frame>Day 7 (± 2)</time_frame>
    <description>Yes/no</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of Symptomatic deep vein thrombosis in legs</measure>
    <time_frame>Day 7 (± 2)</time_frame>
    <description>Yes/non</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of proximal Symptomatic deep vein thrombosis in legs</measure>
    <time_frame>Day 7 (± 2)</time_frame>
    <description>Yes/no</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of distal Symptomatic deep vein thrombosis in legs</measure>
    <time_frame>Day 7 (± 2)</time_frame>
    <description>Yes/no</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of muscular Symptomatic deep vein thrombosis in legs</measure>
    <time_frame>Day 7 (± 2)</time_frame>
    <description>Yes/no</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of any kind of Symptomatic deep vein thrombosis in legs except muscular</measure>
    <time_frame>Day 7 (± 2)</time_frame>
    <description>Yes/no</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of proximal asymptomatic deep vein thrombosis in legs by doppler ultrasound</measure>
    <time_frame>Day 7 (± 2)</time_frame>
    <description>Yes/no</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of distal asymptomatic deep vein thrombosis in legs by doppler ultrasound</measure>
    <time_frame>Day 7 (± 2)</time_frame>
    <description>Yes/no</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of muscular asymptomatic deep vein thrombosis in legs by doppler ultrasound</measure>
    <time_frame>Day 7 (± 2)</time_frame>
    <description>Yes/no</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of any kind of asymptomatic deep vein thrombosis except muscular in legs by doppler ultrasound</measure>
    <time_frame>Day 7 (± 2)</time_frame>
    <description>Yes/no</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">314</enrollment>
  <condition>Deep Vein Thrombosis</condition>
  <condition>Total Hip Prosthesis</condition>
  <condition>Knee Prosthesis</condition>
  <arm_group>
    <arm_group_label>interventional group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood test</intervention_name>
    <description>Additional blood test of 4,5 ml of venous blood</description>
    <arm_group_label>interventional group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Doppler ultrasound</intervention_name>
    <description>Vascular ultrasonic vascular exploration of the lower limbs</description>
    <arm_group_label>interventional group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The patient must have his consent and signed the consent form.&#xD;
&#xD;
          -  The patient must affiliated or a beneficiary of a health insurance plan.&#xD;
&#xD;
          -  The patient is at least 18 years old&#xD;
&#xD;
          -  Patient with an indication of total hip prosthesis or total knee replacement surgery&#xD;
             set unilateral&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The patient is participating in another interventional study.&#xD;
&#xD;
          -  The patient is in an exclusion period determined by a previous study.&#xD;
&#xD;
          -  Minor patients, people in emergency situations.&#xD;
&#xD;
          -  The patient is under the protection of justice, guardianship or curatorship.&#xD;
&#xD;
          -  The patient refuses to sign the consent.&#xD;
&#xD;
          -  It is not possible to inform the patient.&#xD;
&#xD;
          -  The patient is pregnant, parturient, or breastfeeding.&#xD;
&#xD;
          -  The patient has a contraindication (or incompatible drug combination) to drug&#xD;
             thromboprophylaxis applied according to good clinical practice and recommendations of&#xD;
             learned societies&#xD;
&#xD;
          -  Long-term anticoagulant therapy for personal thrombotic history.&#xD;
&#xD;
          -  Known hemorrhagic disease.&#xD;
&#xD;
          -  Haemorrhagic risk perceived during the consultation of preoperative anesthesia,&#xD;
             leading to modify / develop the usual thromboprophylaxis.&#xD;
&#xD;
          -  Chronic liver disease.&#xD;
&#xD;
          -  Chronic renal failure with calculated clearance &lt;30 ml / min.&#xD;
&#xD;
          -  Extreme body mass index: &lt;18 kg.m-2 or&gt; 40 kg.m-2&#xD;
&#xD;
          -  total hip prosthesis or total knee prosthesis in the immediate aftermath of a bone&#xD;
             fracture.&#xD;
&#xD;
          -  total hip prosthesis resumption.&#xD;
&#xD;
          -  Installation of more than one joint prosthesis.&#xD;
&#xD;
          -  Surgery in the previous 3 months.&#xD;
&#xD;
          -  Infective push in the previous 3 months.&#xD;
&#xD;
          -  Indication of haemostatic treatment for abnormal haemorrhagic risk.&#xD;
&#xD;
          -  Severe impairment of renal function with a calculated clearance &lt;30 ml / min.&#xD;
&#xD;
          -  Contraindication (allergic, metabolic, other ...) to usual drug thromboprophylaxis.&#xD;
&#xD;
          -  Condition requiring dosage adjustment of drug thromboprophylaxis.&#xD;
&#xD;
          -  Indication to put in place intermittent pneumatic compression for perioperative&#xD;
             thromboprophylaxis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eva Cochery-Nouvellon, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire de Nīmes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eva Cochery-Nouvellon, Dr</last_name>
    <phone>04.66.68.32.11</phone>
    <email>eva.nouvellon@chu-nimes.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Nimes University Hospital</name>
      <address>
        <city>Nîmes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anissa Megzari</last_name>
      <phone>+33 (0)4.66.68.42.36</phone>
      <email>drc@chu-nimes.fr</email>
    </contact>
    <investigator>
      <last_name>Eva COCHERY-NOUVELLON, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christophe BOISSON, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philippe CUVILLON, Pr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jacques RIPART, Pr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pascal KOUYOUMDJIAN, Pr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antonia Perez-Martin, Pr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Christophe Gris, Pr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>August 7, 2018</study_first_submitted>
  <study_first_submitted_qc>August 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 16, 2018</study_first_posted>
  <last_update_submitted>March 4, 2021</last_update_submitted>
  <last_update_submitted_qc>March 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

